Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors have transformed the management of advanced non‑small cell lung cancer (NSCLC), but reliable prognostic biomarkers remain limited. The present retrospective, single‑center study evaluated clinical variables and baseline 18F‑fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters in 95 patients with metastatic NSCLC treated with second‑line nivolumab after progression on platinum‑based chemotherapy between January 2021 and August 2025. Whole‑body metabolic tumor volume (MTV), total lesion glycolysis (TLG) and site‑specific maximum standardized uptake value (SUVmax) were derived from pretreatment PET/CT. Progression‑free survival (PFS) and overall survival (OS) were analyzed using Kaplan‑Meier and Cox regression methods. Median PFS and OS were 8.2 and 16.8 months, respectively. High MTV and high TLG, defined using exploratory cohort‑specific median cutoffs, were associated with shorter PFS (P=0.045 and P=0.012, respectively) and shorter OS (MTV, P=0.015; TLG, P=0.002). Higher bone‑metastasis SUVmax was associated with shorter PFS (P=0.020). In exploratory multivariable models, Eastern Cooperative Oncology Group performance status 2‑3 and the presence of brain or adrenal metastases remained associated with shorter PFS and OS, whereas MTV and TLG were not retained. Therefore, baseline metabolic tumor burden showed prognostic associations in univariable analyses but did not demonstrate independent prognostic value after adjustment for major clinical factors. These findings are hypothesis‑generating and require prospective validation before clinical use.
No takes yet. Share an insight, caveat, or question.
Bozkurt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: